Consensus on chronic gastritis in China - second national consensus meeting on chronic gastritis (14-16 september 2006 Shanghai, China)

Journal of Digestive Diseases

Volumn 8, Issue 2, 2007, Pages 107-119

  Fang, Jing Yuan ^a   Liu, Wen Zhong ^a   Shi, Yao ^a   Ge, Zhi Zheng ^a   Xiao, Shu Dong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84876059194     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/j.1443-9573.2007.00295.x     Document Type: Article

References (94)

1. Rugge M, Correa P, Dixon MF et al. Gastric mucosal atrophy: Interobserver consistency using new criteria for classification and grading. Aliment Pharmacol Ther 2002; 16: 1249-59.
2. National Cooperative Group for Prevention and Treatment of Gastric Cancer. The biopsied pathology of gastroduodenal mucosa Shenyang, Liaoning Province: Liaoning People's Publishing House, 1981 (in Chinese).
3. Chinese Society of Gastroenterology Chinese Medical Association. Consensus on chronic gastritis formulated at the national symposium. Chin J Dig Dis 2001; 2: 104-8.
4. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney system. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 1161-81.
5. Rugge M, Genta RM. Staging and grading of chronic gastritis. Hum Pathol 2005; 36: 228-33.
6. Lauwers GY. Defining the pathologic diagnosis of metaplasia, atrophy, dysplasia, and gastric adenocarcinoma. J Clin Gastroenterol 2003; 36 (Suppl 2): S37-S43.
7. Ectors N, Dixon MF. The prognostic value of sulphomucin positive intestinal metaplasia in the development of gastric cancer. Histopathology 1986; 10: 1271-7.
8. El-Zimaity HM, Ramchatesingh J, Saeed MA, Graham DY. Gastric intestinal metaplasia: Subtypes and natural history. J Clin Pathol 2001; 54: 679-83.
9. Fenoglio-Preiser C, Carneiro F, Correa P et al. Gastric carcinoma. In: Hamilton SR, Aaltonen LA, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System. Lyon: IARC Press, 2000: 46-52.
10. Rugge M, Correa P, Dixon MF et al. Gastric dysplasia: The Padova international classification. Am J Surg Pathol 2000; 24: 167-76.
11. Dixon MF. Gastrointestinal epithelial neoplasia: Vienna revisited. Gut 2002; 51: 130-1.
12. Kim S, Harum K, Ito M, Tanaka S, Yoshihara M, Chayama K. Magnifying gastroendoscopy for diagnosis of histologic gastritis in the gastric antrum. Dig Liver Dis 2004; 36: 286-91.
13. Kaminishi M, Yamaguchi H, Nomura S et al. Endoscopic classification of chronic gastritis based on a pilot study by the research society for gastritis. Digestive Endoscopy 2002; 14: 138-51.
14. Sakaki N. Study on the pathological diagnosis of gastritis using magnifying gastroscope. Endoscopia Digestiva 2000; 12: 500-4 (in Japanese).
15. Lang L. Barry Marshall 2005 Nobel laureate in medicine and physiology. Gastroenterology 2005; 129: 1813-4.
16. Warren JR. Gastric pathology associated with Helicobacter pylori. Gastroenterol Clin North Am 2000; 29: 705-51.
17. Marshall BJ, Armstrong JA, McGechie DB, Glancy RJ. Attempt to fulfil Koch's postulates for pyloric Campylobacter. Med J Aust 1985; 142: 436-9.
18. Kuipers EJ, Uyterlinde AM, Pena AS et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet 1995; 345: 1525-8.
19. Asaka M, Sugiyama T, Nobuta A, Kato M, Takeda H, Graham DY. Atrophic gastritis and intestinal metaplasia in Japan: Results of a large multicenter study. Helicobacter 2001; 6: 294-9.
20. Zeng ZR, Hu PJ, Hu S et al. Association of interleukin 1B gene polymorphism and gastric cancers in high and low prevalence regions in China. Gut 2003; 52: 1684-9.
21. El-Omar EM, Carrington M, Chow WH et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404: 398-402.
22. Atherton JC. The pathogenesis of Helicobacter pylori-induced gastro-duodenal diseases. Annu Rev Pathol Mech Dis 2006; 1: 63-96.
23. Liu WZ. H. pylori infection, chronic gastritis and functional dyspepsia. Chin J Dig 2002; 22: 581-2 (in Chinese).
24. Talley NJ, Vakil NB, Moayyedi P. American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology 2005; 129: 1756-80.
25. Sheu BS, Yang HB, Wang YL, Chuang CH, Huang AH, Wu JJ. Pretreatment gastric histology is helpful to predict the symptomatic response after H. pylori eradication in patients with nonulcer dyspepsia. Dig Dis Sci 2001; 46: 2700-7.
26. Zhou L, Sung JJ, Lin S et al. A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chin Med J 2003; 116: 11-4.
27. Lahner E, Bordi C, Cattaruzza MS et al. Long-term follow-up in atrophic body gastritis patients: Atrophy and intestinal metaplasia are persistent lesions irrespective of Helicobacter pylori infection. Aliment Pharmacol Ther 2005; 22: 471-81.
28. Hojo M, Miwa H, Ohkusa T, Ohkura R, Kurosawa A, Sato N. Alteration of histological gastritis after cure of Helicobacter pylori infection. Aliment Pharmacol Ther 2002; 16: 1923-32.
29. Borch K, Jonsson KA, Petersson F, Redeen S, Mardh S, Franzen LE. Prevalence of gastroduodenitis and Helicobacter pylori infection in a general population sample: Relations to symptomatology and life-style. Dig Dis Sci 2000; 45: 1322-9.
30. Redeen S, Petersson F, Jonsson KA, Borch K. Relationship of gastroscopic features to histological findings in gastritis and Helicobacter pylori infection in a general population sample. Endoscopy 2003; 35: 946-50.
31. Annibale B, Negrini R, Caruana P et al. Two-thirds of atrophic body gastritis patients have evidence of Helicobacter pylori infection. Helicobacter 2001; 6: 225-33.
32. Annibale B, Di Giulio E, Caruana P et al. The long-term effects of cure of Helicobacter pylori infection on patients with atrophic body gastritis. Aliment Pharmacol Ther 2002; 16: 1723-31.
33. Vaananen H, Vauhkonen M, Helske T et al. Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: A multicentre study. Eur J Gastroenterol Hepatol 2003; 15: 885-91.
34. Wu KC, Li HT, Qiao TD et al. Diagnosis of atrophic body gastritis in Chinese patients by measuring serum pepsinogen. Chin J Dig Dis 2004; 5: 22-7.
35. Cao Q, Ran ZH, Xiao SD. Screening of atrophic gastritis and gastric cancer using serum pepsinogen, gastrin-17 and Helicobacter pylori IgG antibodies. Chin J Gastroenterol 2006; 11: 388-94 (in Chinese).
36. Malfertheiner P, Megraud F, O'Morain C et al. European Helicobacter pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-80.
37. Chinese Society of Gastroenterology; Chinese Medical Association. Consensus on the management of Helicobacter pylori infection: Tongcheng, Anhui Province, 2003. Chin J Dig Dis 2004; 5: 186-8.
38. Aktas A, Caner B, Ozturk F, Bayhan H, Narin Y, Mentes T. The effect of trimebutine maleate on gastric emptying in patients with non-ulcer dyspepsia. Ann Nucl Med 1999; 13: 231-4. 39 Seno H, Nakase H, Chiba T. Usefulness of famotidine in functional dyspepsia patient treatment: Comparison among prokinetic, acid suppression and antianxiety therapies. Aliment Pharmacol Ther 2005; 21 (Suppl): 32-6.
39. Seno H, Nakase H, Chiba T. Usefulness of famotidine in functional dyspepsia patient treatment: Comparison among prokinetic, acid suppression and antianxiety therapies. Aliment Pharmacol Ther 2005; 21 (Suppl): 32-6.
40. Taylor KM, Harris AW. Itopride for functional dyspepsia. N Engl J Med 2006; 354: 2392 [Author's reply: 2392].
41. Guslandi M, Ferrero S, Fusillo M. Sucralfate gel for symptomatic chronic gastritis: Multicentre comparative trial versus sucralfate suspension. Ital J Gastroenterol 1994; 26: 442-5.
42. Haruma K, Ito M. Clinical significance of mucosal-protective agents: Acid, inflammation, carcinogenesis and rebamipide. Aliment Pharmacol Ther 2003; 18 (Suppl): 153-9. [Review article].
43. Liu XG, Jia BQ, Lin SR et al. Teprenone in the treatment of chronic superficial gastritis: A multicenter study. Chin J Intern Med 1996; 35: 12-4 (in Chinese).
44. Ohta Y, Kobayashi T, Imai Y, Inui K, Yoshino J, Nakazawa S. Effect of gefarnate on acute gastric mucosal lesion progression in rats treated with compound 48/80, a mast cell degranulator, in comparison with that of teprenone. Biol Pharm Bull 2005; 28: 1424-30.
45. Pearson JP, Roberts NB. Mucosal protective effects of ecabet sodium: Pepsin inhibition and interaction with mucus. Clin Sci (Lond) 2001; 100: 411-7.
46. Xu GM, Zou DW, Hou XH, Zhao ZH, Domperidone Clinical Research Group. Efficacy of domperidone and hydrotalcid on bile reflux gastritis: A multicenter clinical trail. Chin J Dig Dis 2003; 23: 275-8 (in Chinese).
47. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: A global evidence-based consensus. Am J Gastroenterol 2006; 101: 1900-20; [Quiz: 1943].
48. Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M. A model for gastric cancer epidemiology. Lancet 1975; 2: 58-60.
49. Correa P. A human model of gastric carcinogenesis. Cancer Res 1988; 48: 3554-60.
50. Correa P. Human gastric carcinogenesis: A multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992; 52: 6735-40.
51. Kuipers EJ, Klinkenberg-Knol EC, Vandenbroucke-Grauls CM, Appelmelk BJ, Schenk BE, Meuwissen SG. Role of Helicobacter pylori in the pathogenesis of atrophic gastritis. Scand J Gastroenterol Suppl 1997; 223: 28-34.
52. You WC, Zhang L, Gail MH et al. Gastric dysplasia and gastric cancer: Helicobacter pylori, serum vitamin C, and other risk factors. J Natl Cancer Inst 2000; 92: 1607-12.
53. You WC, Brown LM, Zhang L et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 2006; 98: 974-83.
54. Wong BC, Lam SK, Wong WM et al. China Gastric Cancer Study Group. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: A randomized controlled trial. JAMA 2004; 291: 187-94.
55. Zhou LY, Lin SR, Ding SG et al. Eight-year follow-up study on prevalence of gastric cancer and the histopathological changes of gastric mucosa after H. pylori eradication. Chin J Dig 2005; 25: 324-7 (in Chinese).
56. Nomura A, Grove JS, Stemmermann GN, Severson RK. A prospective study of stomach cancer and its relation to diet, cigarettes, and alcohol consumption. Cancer Res 1990; 50: 627-31.
57. Glade MJ. Food, nutrition, and the prevention of cancer: A global perspective. American Institute for Cancer Research/ World Cancer Res Fund, American Institute for Cancer Research, 1997. Nutrition 1999; 15: 523-6.
58. Lee KW, Lee HJ, Surh YJ, Lee CY. Vitamin C and cancer chemoprevention: Reappraisal. Am J Clin Nutr 2003; 78: 1074-8.
59. Kim DS, Lee MS, Kim YS et al. Effect modification by vitamin C on the relation between gastric cancer and Helicobacter pylori. Eur J Epidemiol 2005; 20: 67-71.
60. Kodama K, Sumii K, Kawano M et al. Gastric juice nitrite and vitamin C in patients with gastric cancer and atrophic gastritis: Is low acidity solely responsible for cancer risk? Eur J Gastroenterol Hepatol 2003; 15: 987-93.
61. Yuan JM, Ross RK, Gao YT, Qu YH, Chu XD, Yu MC. Prediagnostic levels of serum micronutrients in relation to risk of gastric cancer in Shanghai. China Cancer Epidemiol Biomarkers Prev 2004; 13 (11 Pt 1): 1772-80.
62. Taylor PR, Qiao YL, Abnet CC et al. Prospective study of serum vitamin E levels and esophageal and gastric cancers. J Natl Cancer Inst 2003; 95: 1414-6.
63. Jacobs EJ, Connell CJ, McCullough ML et al. Vitamin C, vitamin E, and multivitamin supplement use and stomach cancer mortality in the Cancer Prevention Study II cohort. Cancer Epidemiol Biomarkers Prev 2002; 11: 35-41.
64. Malila N, Taylor PR, Virtanen MJ et al. Effects of alpha-tocopherol and beta-carotene supplementation on gastric cancer incidence in male smokers (ATBC Study, Finland). Cancer Causes Control 2002; 13: 617-23.
65. Qiu JL, Chen K, Zheng JN, Wang JY, Zhang LJ, Sui LM. Nutritional factors and gastric cancer in Zhoushan Islands. China World J Gastroenterol 2005; 11: 4311-6.
66. Prasad KN, Kumar A, Kochupillai V, Cole WC. High doses of multiple antioxidant vitamins: Essential ingredients in improving the efficacy of standard cancer therapy. J Am Coll Nutr 1999; 18: 13-25.
67. van den Brandt PA, Goldbohm RA. Nutrition in the prevention of gastrointestinal cancer. Best Pract Res Clin Gastroenterol 2006; 20: 589-603.
68. Verma A, Atten MJ, Attar BM, Holian O. Selenomethionine stimulates MAPK (ERK) phosphorylation, protein oxidation, and DNA synthesis in gastric cancer cells. Nutr Cancer 2004; 49: 184-90.
69. Zhang L, Blot WJ, You WC et al. Serum micronutrients in relation to pre-cancerous gastric lesions. Int J Cancer 1994; 56: 650-4.
70. Fang JY, Xiao SD, Zhu SS, Yuan JM, Qiu DK, Jiang SJ. Relationship of plasma folic acid and status of DNAmethylation in human gastric cancer. J Gastroenterol 1997; 32: 171-5.
71. Fenech M. The role of folic acid and Vitamin B12 in genomic stability of human cells. Mutat Res 2001; 475: 57-67.
72. Choi SW, Mason JB. Folate status: Effects on pathways of colorectal carcinogenesis. J Nutr 2002; 132 (Suppl): 2413S-8S.
73. Choi SW, Mason JB. Folate and carcinogenesis: An integrated scheme. J Nutr 2000; 130: 129-32.
74. Wang X, Thomas P, Xue J, Fenech M. Folate deficiency induces aneuploidy in human lymphocytes in vitro-evidence using cytokinesis-blocked cells and probes specific for chromosomes 17 and 21. Mutat Res 2004; 551: 167-80.
75. Mayne ST, Risch HA, Dubrow R et al. Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 2001; 10: 1055-62.
76. Fang JY, Xiao SD. Folic acid, polymorphism of methyl-group metabolism genes, and DNA methylation in relation to GI carcinogenesis. J Gastroenterol 2003; 38: 821-9.
77. Xiao SD, Meng XJ, Shi Y, Hu YB, Zhu SS, Wang CW. Interventional study of high dose folic acid in gastric carcinogenesis in beagles. Gut 2002; 50: 61-4.
78. Zhu S, Mason J, Shi Y et al. The effect of folic acid on the development of stomach and other gastrointestinal cancers. Chin Med J (Engl) 2003; 116: 15-9.
79. Sun CL, Yuan JM, Lee MJ et al. Urinary tea polyphenols in relation to gastric and esophageal cancers: A prospective study of men in Shanghai, China. Carcinogenesis 2002; 23: 1497-503.
80. Setiawan VW, Zhang ZF, Yu GP et al. Protective effect of green tea on the risks of chronic gastritis and stomach cancer. Int J Cancer 2001; 92: 600-4.
81. Amagase H. Clarifying the real bioactive constituents of garlic. J Nutr 2006; 136 (Suppl): 716S-25S.
82. Rivlin RS. Is garlic alternative medicine? J Nutr 2006; 136 (Suppl): 713S-5S.
83. Sengupta A, Ghosh S, Bhattacharjee S. Allium vegetables in cancer prevention: An overview. Asian Pac J Cancer Prev 2004; 5: 237-45.
84. You WC, Zhang L, Gail MH et al. Helicobacter pylori infection, garlic intake and precancerous lesions in a Chinese population at low risk of gastric cancer. Int J Epidemiol 1998; 27: 941-4.
85. Iimuro M, Shibata H, Kawamori T et al. Suppressive effects of garlic extract on Helicobacter pylori-induced gastritis in Mongolian gerbils. Cancer Lett 2002; 187: 61-8.
86. You WC, Blot WJ, Chang YS et al. Allium vegetables and reduced risk of stomach cancer. J Natl Cancer Inst 1989; 81: 162-4.
87. Nardone G, Rocco A, Malfertheiner P. Review article: Helicobacter pylori and molecular events in precancerous gastric lesions. Aliment Pharmacol Ther 2004; 20: 261-70.
88. Li XB, Liu WZ, Xu WW, Shi Y, Xiao SD. Prevalence of cagA, cagE and cagT genes in cag pathogenicity island of Helicobacter pylori strains isolated from Shanghai patients and their clinical implications. Chin J Dig 2000; 20: 371-3 (in Chinese).
89. Han YH, Liu WZ, Zhu HY, Xiao SD. Helicobacter pylori iceA and babA2 genotype and its clinical association in Shanghai area. Chin J Dig 2004; 24: 322-5 (in Chinese).
90. Madisch A, Miehlke S, Neuber F et al. Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy-a randomized, double-blind, placebo-controlled multicentre trial. Aliment Pharmacol Ther 2006; 23: 473-9.
91. Santolaria Piedrafita S, Conde Garcia R, Abascal Agorreta M et al. Resolution of Ménétrier's disease after eradication of Helicobacter pylori infection. Gastroenterol Hepatol 2004; 27: 357-61.
92. Yoshimura M, Hirai M, Tanaka N, Kasahara Y, Hosokawa O. Remission of severe anemia persisting for over 20 years after eradication of Helicobacter pylori in cases of Ménétrier's disease and atrophic gastritis: Helicobacter pylori as a pathogenic factor in iron-deficiency anemia. Intern Med 2003; 42: 971-7.
93. D'Elios MM, Appelmelk BJ, Amedei A, Bergman MP, Del Prete G. Gastric autoimmunity: The role of Helicobacter pylori and molecular mimicry. Trends Mol Med 2004; 10: 316-23.
94. Reid ME, Stratton MS, Lillico AJ et al. A report of high-dose selenium supplementation: Response and toxicities. J Trace Elem Med Biol 2004; 18: 69-74.